Count the patients: this season's best growth is demand you can measure

The number behind the number

Third-quarter reports are full of headline growth. Corcept posted revenue of $340.5 million, up 64 percent. Madrigal reported Rezdiffra net sales of $431.3 million, up 50 percent. ANI's net revenues rose 27.6 percent to $290.8 million. Ironwood raised its LINZESS U.S. net sales guidance to $1.20 to $1.25 billion. Revenue growth like this is easy to announce. The more useful question is what sits underneath it.

Two of the companies answered that question directly. Madrigal said more than 55,850 patients were on Rezdiffra at September 30, nearly double the level a year earlier. It also said the U.S. F2-F3 MASH market had grown to more than 530,000 addressable patients through June 30, on track for more than 30 percent growth by year-end. Harmony said WAKIX added 400 net patients in the quarter, supporting $269 million in revenue and a reiterated full-year guide of $1.0 billion to $1.04 billion.

Our position is that this is the standard for the season. A quarter anchored in patients on therapy and a quantified market tells an investor, a payer and a partner far more than a percentage change does. It shows where the next quarter's revenue comes from.

Access is what turns patients into revenue

Krystal shows the other side of the argument. It reported $127.3 million in VYJUVEK global revenue for the quarter and $1.1 billion since launch. It also noted that pricing negotiations in Germany and Italy are complete. That detail is easy to skip, but it marks the point where a launch outside the U.S. stops being a plan and starts being a revenue line. Demand that has cleared the pricing gate is a different kind of asset from demand that is still waiting at it.

The same logic applies to the mature franchises. Ironwood said year-to-date LINZESS U.S. net sales of $880 million already exceed the full-year 2025 figure. ANI's Purified Cortrophin Gel grew 36.1 percent. Neither release, in the portions we have, breaks that growth into patients and other drivers. That is a gap, and a more transparent company would close it.

The strongest counter-argument

Patient counts are not revenue, and they can flatter. Madrigal's own numbers show the tension: patients nearly doubled year on year while net sales grew 50 percent. The material does not explain the difference, and several things could contribute, such as timing, duration of therapy or net price. The point is that a rising patient count does not on its own prove rising revenue per patient. Metrics are also chosen by the companies reporting them. Harmony's net adds are encouraging, but they sit alongside a stated exclusivity runway to March 2030 and active legal proceedings, and a patient base does not by itself answer that horizon.

We accept this. Patient metrics are a necessary disclosure, not a sufficient one. But the alternative is worse. A reported growth rate with no volume context asks the reader to take durability on trust, and in a season where several companies have raised or reiterated guidance, trust is a thin foundation.

What this means

The companies that look strongest this season are not only those with the biggest percentage gains. They are those whose growth can be traced to people starting and staying on therapy, in a market whose size they can state. The rest are asking for credit on a rate alone.

— The Editor, CompePharma